ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
0,095
0,015
( 18,75% )
Aktualisiert: 20:01:38

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

Current Price
0,095
Gebot
0,09
Fragen
0,095
Volumen
391.356
0,09 Tagesbereich 0,095
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
0,08
Handelsbeginn
0,09
Letzte Trade
20000
@
0.095
Letzter Handelszeitpunkt
20:38:23
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
697.445.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-23,68
Gewinn pro Aktie (EPS)
-0
Erlöse
432k
Nettogewinn
-2,68M

Über MedMira Inc

Sektor
In Vitro,in Vivo Diagnostics
Branche
In Vitro,in Vivo Diagnostics
Website
Hauptsitz
Halifax, Nova Scotia, Can
Gegründet
-
MedMira Inc is listed in the In Vitro,in Vivo Diagnostics sector of the TSX Venture Börse with ticker MIR. The last closing price for MedMira was $0,08. Over the last year, MedMira shares have traded in a share price range of $ 0,00 to $ 0,00.

MedMira currently has 697.445.000 shares in issue. The market capitalisation of MedMira is $55,80 million. MedMira has a price to earnings ratio (PE ratio) of -23.68.

MIR Neueste Nachrichten

MedMira Strengthens and Expands Board

HALIFAX, Nova Scotia, July 14, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the Board of Directors. In addition, Mr. Thomas...

MedMira Reports Third Quarter Results FY2022

HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022. Profit and Loss...

MedMira Receives Patent for its Unique Quantitative Diagnostic System

HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and...

MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market

HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark...

VYRA™ Product Line Update

HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the...

MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE...

MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in...

MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test

HALIFAX, Nova Scotia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) has received the CE mark for its REVEALCOVID-19® PLUS Total Antibody Test. The test will be...

MedMira Provides a Pre-Annual General Meeting Update

HALIFAX, Nova Scotia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development...

MedMira Reports First Quarter Results FY2022

HALIFAX, Nova Scotia, Dec. 30, 2021 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2021. Profit and Loss...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
RPRepliCel Life Sciences Inc
$ 0,02
(100,00%)
437k
TBIXTrustbix Inc
$ 0,02
(100,00%)
10k
KTRKintavar Exploration Inc
$ 0,015
(50,00%)
58k
MINEInomin Mines Inc
$ 0,05
(42,86%)
730,04k
SLMNSolis Minerals Ltd
$ 0,12
(41,18%)
1.000
AVII.PAntera Ventures II Corp
$ 0,03
(-68,42%)
11,15k
PLRBPluribus Technologies Corp
$ 0,03
(-66,67%)
3k
TVC.HThree Valley Copper Corp
$ 0,005
(-50,00%)
2,13M
FV.HFirestone Ventures Inc
$ 0,05
(-50,00%)
104,5k
IBOUniversal Ibogaine Inc
$ 0,005
(-50,00%)
10,03k
TVC.HThree Valley Copper Corp
$ 0,005
(-50,00%)
2,13M
KLMKermode Resources Ltd
$ 0,005
(0,00%)
1,84M
FUUF3 Uranium Corp
$ 0,235
(-6,00%)
1,47M
PAPalamina Corp
$ 0,145
(-38,30%)
1,39M
MGMMaple Gold Mines Ltd
$ 0,065
(-13,33%)
1,29M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht